Ascendis Pharma A/S (ASND) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$238.15

From 52W high−14.60%

Volume1.49M

Market cap$15.57B

P/E (TTM)17.0x

P/S (TTM)12.9x

Div yield—

Key dataSep 18, 2026

Open

$238.15

From 52W high

−14.60%

Volume

1.49M

Market cap

$15.57B

ValuationView details →

P/E (Fwd)

33.3x

EV/EBITDA

169.0x

P/E (TTM)

17.0x

RSI (14)

39.0

MomentumView details →

1D Return

−0.97%

YTD Return

+12.43%

SummaryUpdated Jun 1, 2026

Ascendis Pharma A/S (NASDAQ:ASND) is a Danish biopharmaceutical company founded in 2006 and headquartered in Hellerup, Denmark. The company went public on NASDAQ in January 2015. Ascendis specializes in developing innovative therapeutics for rare endocrine diseases using its proprietary TransCon technology platform, which enables the creation of long-acting versions of existing drugs. The company has successfully commercialized two products and maintains a robust pipeline of treatments targeting unmet medical needs in endocrinology and oncology.

Ask drillr about Ascendis Pharma A/S →

ValuationView details →

P/E (Fwd)

33.3x

P/E (TTM)

17.0x

EV/EBITDA

169.0x

EV/Sales

12.5x

P/S (TTM)

12.9x

P/B (TTM)

9.4x

ProfitabilityView details →

Gross Margin

90.19%

Net Margin

71.69%

EBITDA Margin

7.41%

ROE (TTM)

52.64%

ROA (TTM)

33.08%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

+114.85%

EPS YoY

+365.93%

FCF YoY

+297.19%

Revenue CAGR 3Y

+138.21%

EPS CAGR 3Y

+44.56%

EBITDA YoY

+151.76%

MomentumView details →

1D Return

−0.97%

YTD Return

+12.43%

1Y Return

+21.28%

RSI (14)

39.0

vs 50D SMA

−5.94%

vs 200D SMA

+2.27%

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

2.99x

Quick Ratio

2.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.29

EPS Surprise

117.88%

Beats (12Q)

7/12

Next Q EPS Est

$1.08

Avg Surprise (4Q)

−245.44%

Rev Surprise

1.18%

Financials snapshotView financials →

Revenue (TTM)

1.05B

Net Income (TTM)

755.85M

Op. CF (TTM)

351.32M

Next earningsNov 11, 2026 →

Latest newsMore news →

Ascendis Pharma A/S announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.6d ago

Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.6d ago

Similar companies

Jazz Pharmaceuticals plcJAZZ Exelixis, Inc.EXEL Summit Therapeutics Inc.SMMT 神州细胞688520.SH Xcell Therapeutics, Inc.373110.KQ 生物股份600201.SH Find similar companies →

Latest newsMore news →

Ascendis Pharma A/S announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.6d ago Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.6d ago